Patents by Inventor Robert R. Garrity

Robert R. Garrity has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
    Patent number: 5853724
    Abstract: The present invention provides a vaccine that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The vaccine includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The vaccine also includes a pharmacologically acceptable carrier.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: December 29, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert R. Garrity, Peter L. Nara, Jaap Goudsmit
  • Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
    Patent number: 5585250
    Abstract: The present invention provides a composition that can be administered to a mammal to cause immunoprotection in the mammal against a pathogenic organism that has an immunodominant epitope. The composition includes a modified form of the antigen in which the immunodominant epitope is located. In this modified form, the immunodominant epitope is immunodampened by any of a number of techniques. Examples of immunodampening techniques include addition of N-linked glycosylation sites, change of the net charge on the epitope, and substitution with a tolerated sequence. The composition also includes a pharmacologically acceptable carrier.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: December 17, 1996
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Robert R. Garrity, Peter L. Nara, Jaap Goudsmit